Distinguished in Acute Lymphoblastic Leukemia (ALL)

Dr. Andrew E. Place

Pediatric Hematology Oncology
300 Longwood Ave, Department Of Hematology And Oncology, 
Boston, MA 
Distinguished in Acute Lymphoblastic Leukemia (ALL)
300 Longwood Ave, Department Of Hematology And Oncology, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Andrew Place is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Place is rated as a Distinguished provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Acute Megakaryoblastic Leukemia, Leukemia, and Infantile Neutropenia.

His clinical research consists of co-authoring 44 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 23 articles and participated in 5 clinical trials in the study of Acute Lymphoblastic Leukemia (ALL).

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in MA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
NH Healthy Families
  • EPO
  • MANAGED MEDICAID PLAN
Tufts
  • HMO
View 1 Less Insurance Carrier -

Locations

300 Longwood Ave, Department Of Hematology And Oncology, Boston, MA 02115

Additional Areas of Focus

Dr. Place has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
Enrollment Status: Terminated
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 1/Phase 2
A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies
A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Biological
Study Drug: CTL019
Study Phase: Phase 2
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML.
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML.
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2025
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 1
Phase I Trial of Ribociclib in Combination With Everolimus and Dexamethasone in Children and Young Adults With Relapsed Acute Lymphoblastic Leukemia
Phase I Trial of Ribociclib in Combination With Everolimus and Dexamethasone in Children and Young Adults With Relapsed Acute Lymphoblastic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Drug
Study Drugs: Ribociclib, Dexamethasone, Everolimus
Study Phase: Phase 1
Matched Targeted Therapy (MTT) Recommendation for Patients With Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic Syndrome
Matched Targeted Therapy (MTT) Recommendation for Patients With Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: April 23, 2025
Intervention Type: Genetic
Study Phase: Not Applicable
Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML
Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML
Enrollment Status: Completed
Publish Date: June 24, 2022
Intervention Type: Drug
Study Drugs: Decitabine, Vorinostat, Filgrastim, Fludarabine, Cytarabine
Study Phase: Phase 1
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study (AflacLL1401)
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study (AflacLL1401)
Enrollment Status: Withdrawn
Publish Date: April 19, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

44 Total Publications

Seizing the policy opportunities for health- and equity-improving energy decisions.
Seizing the policy opportunities for health- and equity-improving energy decisions.
Journal: One earth (Cambridge, Mass.)
Published: July 21, 2025
Similar Doctors
Elite in Acute Lymphoblastic Leukemia (ALL)
Dr. Lewis B. Silverman
Pediatric Hematology Oncology
Elite in Acute Lymphoblastic Leukemia (ALL)
Dr. Lewis B. Silverman
Pediatric Hematology Oncology
44 Binney St, Dana Farber Cancer Institute, 
Boston, MA 
 (0.1 miles away)
617-632-5285
Languages Spoken:
English
See accepted insurances

Lewis Silverman is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Silverman is rated as a Distinguished provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Adult T-Cell Leukemia, and Kienbock's Disease.

Elite in Acute Lymphoblastic Leukemia (ALL)
Dr. Stephen E. Sallan
Pediatric Hematology Oncology
Elite in Acute Lymphoblastic Leukemia (ALL)
Dr. Stephen E. Sallan
Pediatric Hematology Oncology
450 Brookline Avenue, Room 1642, 
Boston, MA 
 (0.1 miles away)
617-632-3316
Languages Spoken:
English
See accepted insurances

Stephen Sallan is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Sallan is rated as a Distinguished provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are NUT Carcinoma, Acute Lymphoblastic Leukemia (ALL), Leukemia, and Adult T-Cell Leukemia.

Distinguished in Acute Lymphoblastic Leukemia (ALL)
Dr. Lynda M. Vrooman
Pediatric Hematology Oncology
Distinguished in Acute Lymphoblastic Leukemia (ALL)
Dr. Lynda M. Vrooman
Pediatric Hematology Oncology
Boston, MA 
 (0.1 miles away)
617-632-2659
Languages Spoken:
English
See accepted insurances

Lynda Vrooman is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Vrooman is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Acute Megakaryoblastic Leukemia, and Kienbock's Disease.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Place's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile